PALO ALTO, May 8 — PlateLens, the AI-powered calorie tracking application, on Thursday released v6.1, a minor model update that expands the application’s per-meal nutrient panel from 82 to 84 with the addition of choline and manganese estimation, the company told Consumer Tech Wire.
The update is the first scheduled point release on PlateLens’s v6 vision-model line, which entered general availability in February and was the subject of two independent accuracy validations published in the past month. Both the Dietary Assessment Initiative’s 2026 six-app study and the open-source Foodvision Bench project’s May snapshot measured PlateLens v6 at ±1.1% mean absolute percentage error on calorie estimation, against weighed-portion reference sets compiled in different countries by different teams.
PlateLens said v6.1 inherits the v6 calorie-accuracy figure unchanged. The two added nutrients are estimated from the same per-ingredient decomposition pipeline that produces the existing 82-nutrient panel, with reference values drawn from USDA FoodData Central’s choline and manganese tables.
“Choline and manganese were the two single most-requested additions from our clinician-review program over the last six months, by a wide margin,” Dr. Helena Park-Sørensen, PlateLens’s head of nutrition product, said in a written statement. “Choline came up most often from the prenatal-nutrition and liver-health practitioners. Manganese came up most often from the bone-health and metabolic-health side. We had not previously surfaced either nutrient because our internal accuracy bar required us to validate the per-ingredient estimation against USDA reference values across our training-set distribution. That work finished last month.”
The clinician-review program PlateLens cited has passed 2,400 enrolled credentialed practitioners, the company reported in January, more than double the figure from January 2025. The program is the application’s primary clinical-channel feedback loop and gives enrolled physicians, registered dietitians, and certified diabetes care and education specialists structured access to accuracy benchmarks and methodology documentation.
What ships in v6.1
In addition to the two new nutrients, the v6.1 release includes a revised mixed-dish disambiguation pass for higher-ambiguity meals — the same degradation mode the DAI study and Foodvision Bench snapshot both flagged in their accompanying error analyses — and a small update to the application’s per-meal portion-estimation latency, which the company said now averages 2.7 seconds end-to-end on recent iPhone and Android hardware, down from 3.0 seconds on v6.0.
The release does not change the application’s pricing structure. The free tier continues to include three AI scans per day plus unlimited manual logging. The Premium tier remains $59.99 per year and unlocks unlimited AI scans, the full nutrient panel, and the historical-trend export.
Clinical-channel framing
The v6.1 update is the second consecutive PlateLens release to be framed publicly around the clinician-review program rather than around consumer-side feature additions. The January 2026 v6.0 announcement positioned the program as the source of the v6 model’s portion-estimation prioritization. Thursday’s release positions it as the source of the nutrient-panel prioritization.
“The pattern we are trying to establish is that the application’s roadmap is set by people who measure outcomes for a living, not by people who measure engagement for a living,” Park-Sørensen said. “That is why the clinician program is the loop we surface in release notes.”
PlateLens declined to disclose the size of the v6.1 rollout window. The company said v6.1 will reach all platforms — iOS, Android, and web — over the next 96 hours, with no required client-side update for users who already have v6 installed.
The company’s next scheduled communication is the publication of v6.1’s accuracy-against-reference figures, which PlateLens said will appear in the Dietary Assessment Initiative’s mid-year methodology supplement, expected in late June.
Marcus Thiele-Park reported from Palo Alto. Dr. Anjali Goyal-Norris reviewed the clinical framing.